Asia-Pacific Biomarkers for Hematopathology Market Research Report Information by Type (Products and Services), by Cancer Type (Lymphoma and Leukemia), by Technology Category (NGS, PCR, IHC, FISH and Others), by Region Forecast to 2032
Market Overview
The Asia-Pacific Biomarkers for Hematopathology Market is expected to grow at a CAGR of 9.22% over the study period. Biomarkers for hematopathology are biological molecules present in blood, tissues, or bone marrow that serve as indicators for a wide range of hematological illnesses, including leukemia, lymphoma, anemia, and myeloproliferative diseases. These biomarkers are typically proteins, genes, or metabolites that may be detected and quantified using advanced diagnostic techniques like flow cytometry, PCR, immunohistochemistry, and next-generation sequencing (NGS). Biomarkers are essential in hematopathology for diagnosing, prognosing, and assessing treatment response in blood cancer and other hematological illnesses.
The Asia-Pacific biomarker market for hematopathology is being driven by the rising prevalence of blood-related cancers and the increased emphasis on early diagnosis. Furthermore, collaborations to identify biomarkers for blood malignancies are driving market expansion. Furthermore, poor healthcare infrastructure in remote areas and a lack of skilled personnel are impeding the growth of the Asia-Pacific biomarkers for hematopathology market. However, the expanding geriatric population, as well as ongoing research into biomarkers for early detection, will present future growth possibilities for the market.
Marketing Segmentation
The Asia-Pacific Biomarkers for Hematopathology market is divided into two segments: products and services.
The market has been divided into two segments based on cancer type: lymphoma and leukemia. The Lymphoma category dominated the market in 2023 and is expected to be the fastest-growing sector during the forecast period (2024-2032).
The market is divided into technology categories, which include NGS, PCR, IHC, FISH, and others.
The Asia-Pacific (APAC) market for biomarkers in hematopathology is expanding rapidly, owing to a variety of causes such as an increase in the incidence of hematological tumors, advances in molecular diagnostics, and a growing emphasis on personalized and precision medicine. Hematological illnesses such as leukemia, lymphoma, and myeloma are growing more common in the region, necessitating the development of sophisticated diagnostic methods and biomarkers that allow for more precise and timely detection. Leukemia, particularly acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) is on the rise, with biomarkers including BCR-ABL1, FLT3, and IDH1/IDH2 playing important roles in diagnosis, prognosis, and treatment monitoring. For example, in 2020, South Asia recorded 1,733,573 cancer cases, with leukemia accounting for 62,163 (3.59%). There were 36,315 males and 25,848 women diagnosed with leukemia.
Major Players
The market's major companies are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Merck KGaA, Becton, Agilent Technologies Inc., Dickinson and Company, and PerkinElmer.
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 30
TABLE 2 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 47
TABLE 3 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR PRODUCT, BY COUNTRY, 2019–2032 (USD THOUSANDS) 48
TABLE 4 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR SERVICE, BY COUNTRY, 2019–2032 (USD THOUSANDS) 49
TABLE 5 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 52
TABLE 6 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 52
TABLE 7 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR LYMPHOMA, BY COUNTRY, 2019–2032 (USD THOUSANDS) 53
TABLE 8 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR LEUKEMIA, BY COUNTRY, 2019–2032 (USD THOUSANDS) 54
TABLE 9 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 57
TABLE 10 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR NGS, BY COUNTRY, 2019–2032 (USD THOUSANDS) 58
TABLE 11 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR PCR, BY COUNTRY, 2019–2032 (USD THOUSANDS) 59
TABLE 12 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR IHC, BY COUNTRY, 2019–2032 (USD THOUSANDS) 60
TABLE 13 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR FISH, BY COUNTRY, 2019–2032 (USD THOUSANDS) 61
TABLE 14 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR OTHERS, BY COUNTRY, 2019–2032 (USD THOUSANDS) 62
TABLE 15 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY COUNTRY, 2019–2032 (USD THOUSANDS) 65
TABLE 16 CHINA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 66
TABLE 17 CHINA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 67
TABLE 18 CHINA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 67
TABLE 19 CHINA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 67
TABLE 20 JAPAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 68
TABLE 21 JAPAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 68
TABLE 22 JAPAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 68
TABLE 23 JAPAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 69
TABLE 24 INDIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 69
TABLE 25 INDIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 69
TABLE 26 INDIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 70
TABLE 27 INDIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 70
TABLE 28 AUSTRALIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 70
TABLE 29 AUSTRALIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 71
TABLE 30 AUSTRALIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 71
TABLE 31 AUSTRALIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 71
TABLE 32 SOUTH KOREA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 72
TABLE 33 SOUTH KOREA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 72
TABLE 34 SOUTH KOREA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 72
TABLE 35 SOUTH KOREA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 73
TABLE 36 TAIWAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 73
TABLE 37 TAIWAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 73
TABLE 38 TAIWAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 74
TABLE 39 TAIWAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 74
TABLE 40 SINGAPORE BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 74
TABLE 41 SINGAPORE BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 75
TABLE 42 SINGAPORE BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 75
TABLE 43 SINGAPORE BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 75
TABLE 44 NEW ZEALAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 76
TABLE 45 NEW ZEALAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 76
TABLE 46 NEW ZEALAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 76
TABLE 47 NEW ZEALAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 77
TABLE 48 HONG KONG BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 77
TABLE 49 HONG KONG BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 77
TABLE 50 HONG KONG BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 78
TABLE 51 HONG KONG BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 78
TABLE 52 THAILAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 78
TABLE 53 THAILAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 79
TABLE 54 THAILAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 79
TABLE 55 THAILAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 79
TABLE 56 INDONESIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 80
TABLE 57 INDONESIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 80
TABLE 58 INDONESIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 80
TABLE 59 INDONESIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 81
TABLE 60 VIETNAM BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 81
TABLE 61 VIETNAM BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 81
TABLE 62 VIETNAM BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 82
TABLE 63 VIETNAM BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 82
TABLE 64 MALAYSIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 82
TABLE 65 MALAYSIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 83
TABLE 66 MALAYSIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 83
TABLE 67 MALAYSIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 83
TABLE 68 PHILIPPINES BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019–2032 (USD THOUSANDS) 84
TABLE 69 PHILIPPINES BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (USD THOUSANDS) 84
TABLE 70 PHILIPPINES BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019–2032 (VOLUME) 84
TABLE 71 PHILIPPINES BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019–2032 (USD THOUSANDS) 85
TABLE 72 PRODUCT LAUNCH 91
TABLE 73 PRODUCT APPROVAL 91
TABLE 74 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 94
TABLE 75 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 94
TABLE 76 MERCK KGAA: PRODUCTS OFFERED 98
TABLE 77 AGILENT TECHNOLOGIES INC.: PRODUCTS OFFERED 102
TABLE 78 AGILENT TECHNOLOGIES INC.: PRODUCTS OFFERED 103
TABLE 79 PERKINELMER: PRODUCTS OFFERED 106
TABLE 80 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS OFFERED 108
TABLE 81 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 111
TABLE 82 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERED 116
TABLE 83 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 119
TABLE 84 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS OFFERED 123
TABLE 85 ABCAM LIMITED: PRODUCTS OFFERED 125
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET: STRUCTURE 18
FIGURE 2 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 34
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 36
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 37
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET 39
FIGURE 6 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSANDS) 47
FIGURE 7 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2023 & 2032 (USD THOUSANDS) 47
FIGURE 8 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET SHARE (%), BY TYPE, 2023 48
FIGURE 9 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, CANCER TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSANDS) 51
FIGURE 10 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2023 & 2032 (USD THOUSANDS) 51
FIGURE 11 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET SHARE (%), BY CANCER TYPE, 2023 52
FIGURE 12 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSANDS) 56
FIGURE 13 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2023 & 2032 (USD THOUSANDS) 56
FIGURE 14 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET SHARE (%), BY TECHNOLOGY, 2023 57
FIGURE 15 ASIA-PACIFIC MARKET ANALYSIS: BIOMARKERS FOR HEMATOPATHOLOGY MARKET, 2019-2032 (USD THOUSANDS) 64
FIGURE 16 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY COUNTRY, 2023 & 2032 (USD THOUSANDS) 65
FIGURE 17 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET SHARE (%), BY COUNTRY, 2023 66
FIGURE 18 ASIA PACIFIC IHC BIOMARKERS FOR HEMATOPATHOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 87
FIGURE 19 ASIA PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023 88
FIGURE 20 COMPETITOR DASHBOARD: ASIA PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET 89
FIGURE 21 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT 93
FIGURE 22 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 95
FIGURE 23 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT 97
FIGURE 24 MERCK KGAA: SWOT ANALYSIS 98
FIGURE 25 AGILENT TECHNOLOGIES INC.: FINANCIAL OVERVIEW SNAPSHOT 101
FIGURE 26 PERKINELMER: FINANCIAL OVERVIEW SNAPSHOT 106
THIS IS A PRIVATELY HELD COMPANY. THEREFORE, FINANCIALS ARE NOT AVAILABLE IN THE PUBLIC DOMAIN. 108
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 111
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 113
FIGURE 29 BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 115
FIGURE 30 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS 117
FIGURE 31 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW 118
FIGURE 32 BIO-RAD LABORATORIES, INC: SWOT ANALYSIS 121
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們